Epigenetic control of gene function in schistosomes: A source of therapeutic targets?

Frontiers in Genetics

Volumn 5, Issue SEP, 2014, Pages

  Cabezas Cruz, Alejandro ^a   Lancelot, Julien ^a   Caby, Stéphanie ^a   Oliveira, Guilherme ^b   Pierce, Raymond J ^a  

^a UNIV LILLE   (France)

^b INSTITUTO OSWALDO CRUZ   (Brazil)

Author keywords

DNA methylation; Drug discovery; Epigenetics; Histone modifying enzymes; MicroRNAs; Schistosome

Indexed keywords

COMPLEMENTARY DNA; DNA METHYLTRANSFERASE; HISTONE DEMETHYLASE; MICRORNA; SMALL INTERFERING RNA;

CELL DIFFERENTIATION; CELL SURVIVAL; DEVELOPMENTAL BIOLOGY; DNA METHYLATION; DNA SEQUENCE; ENZYME ACTIVITY; EPIGENETICS; GENE EXPRESSION; GENE FUNCTION; GENETIC REGULATION; GENETIC TRANSCRIPTION; MOLECULAR GENETICS; NONHUMAN; REVIEW; RNA INTERFERENCE; SCHISTOSOMA MANSONI; SCHISTOSOMIASIS; TRANSLATION INITIATION;

METAZOA; SCHISTOSOMA; SCHISTOSOMA MANSONI; VERTEBRATA;

EID: 84917689592     PISSN: None     EISSN: 16648021     Source Type: Journal    
DOI: 10.3389/fgene.2014.00317     Document Type: Review

References (100)

1. Anderson, L., Pierce, R. J., and Verjovski-Almeida, S. (2012). Schistosoma mansoni histones: from transcription to chromatin regulation; an in silico analysis. Mol. Biochem. Parasitol. 183, 105-114. doi: 10.1016/j.molbiopara.2012.03.001
2. Arrowsmith, C. H., Bountra, C., Fish, P. V., Lee, K., and Schapira, M. (2012). Epigenetic protein families: a new frontier for drug discovery. Nat. Rev. Drug Discov. 11, 384-400. doi: 10.1038/nrd3674
3. Azzi, A., Cosseau, C., and Grunau, C. (2009). Schistosoma mansoni: developmental arrest of miracidia treated with histone deacetylase inhibitors. Exp. Parasitol. 121, 88-291. doi: 10.1016/j.exppara.2008.11.010
4. Badeaux, A. I., and Shi, Y. (2013). Emerging roles for chromatin as a signal integration and storage platform. Nat. Rev. Mol. Cell Biol. 14, 211-224. doi: 10.1038/nrm3545
5. Bantscheff, M., Hopf, C., Savitski, M. M., Dittmann, A., Grandi, P., Michon, A. M., et al. (2011). Chemoproteomics profiling of HDAC inhibitors reveals selective targeting of HDAC complexes. Nat. Biotechnol. 29, 255-265. doi: 10.1038/nbt.1759
6. Baubec, T., and Schübeler, D. (2014). Genomic patterns and context-specific interpretation of DNA methylation. Genet. Dev. 25, 85-92. doi: 10.1016/j.gde.2013.11.015
7. Berriman, M., Haas, B., Loverde, P. T., Wilson, R. A., Dillon, G. P., Cerqueira, G. C., et al. (2009). The Genome of the blood fluke Schistosoma mansoni. Nature 462, 352-358. doi: 10.1038/nature08160
8. Bertin, B., Oger, F., Cornette, J., Caby, S., Noël, C., Capron, M., et al. (2006). Schistosoma mansoni CBP/P300 has a conserved domain structure and interacts functionally with the nuclear receptor SmFtz-F1. Mol. Biochem. Parasitol. 146, 180-191. doi: 10.1016/j.molbiopara.2005.12.006
9. Bowers, E. M., Yan, G., Mukherjee, C., Orry, A., Wang, L., Holbert, M. A., et al. (2010). Virtual ligand screening of the p300/CBP histone acetyltransferase: identification of a selective small molecule inhibitor. Chem. Biol. 17, 471-482. doi: 10.1016/j.chembiol.2010.03.006
10. Boyle, J. P., Shoemaker, C. B., and Yoshino, T. P. (2003). Using RNA interference to manipulate endogenous gene expression in Schistosoma mansoni sporocysts. Mol. Biochem. Parasitol. 128, 205-215. doi: 10.1016/S0166-6851(03)00078-1
11. Cai, P., Hou, N., Piao, X., Liu, S., Liu, H., Yang, F., et al. (2011). Profiles of small non-coding RNAs in Schistosoma japonicum during development. PLoS Negl. Trop. Dis. 5:e1256. doi: 10.1371/journal.pntd.0001256
12. Carneiro, V. C., de Abreu da Silva, I. C., Torres, E. J., Caby, S., Lancelot, J., Vanderstraete, M., et al. (2014). Epigenetic changes modulate schistosome egg formation and are a novel target for reducing transmission of schistosomiasis. PLoS Pathog. 8:e1004116. doi: 10.1371/journal.ppat.1004116
13. Chung, C.-W., Coste, H., White, J. H., Miguet, O., Wilde, J., Gosmini, R. L., et al. (2011). Discovery and characterization of small molecule inhibitors of the BET family bromodomains. J. Med. Chem. 54, 3827-3838. doi: 10.1021/jm200108t
14. Coeli, R., Baba, E. H., Araujo, N., Coelho, P. M. C. Z., and Oliveira, G. (2013). Praziquantel Treatment Decreases Schistosoma mansoni genetic diversity in experimental infections. PLoS Negl. Trop. Dis. 7:e2596. doi: 10.1371/journal.pntd.0002596
15. Colley, D. G., Bustinduy, A. L., Secor, W. E., and King, C. H. (2014). Human schistosomiasis. Lancet 383, 2253-2264. doi: 10.1016/SD140-6736(13)61949-2
16. Costinean, S., Zanesi, N., Pekarsky, Y., Tili, E., Volinia, S., Heerema, N., et al. (2006). Pre-B cell proliferation and lymphoblastic leukemia /high grade lymphoma in Eμ-miR155 transgenic mice. Proc. Natl. Acad. Sci. U.S.A. 103, 7024-7029. doi: 10.1073/pnas.0602266103
17. Daigle, S. R., Olhava, E. J., Therkelsen, C. A., Basavapathruni, A., Jin, L., Boriack-Sjodin, P. A., et al. (2013). Potent inhibition of DOT1L as treatment for MLL-fusion leukemia. Blood 122, 1017-1025. doi: 10.1182/blood-2013-04-497644
18. Day, T. A., Bennet, J. L., and Pax, R. A. (1992). Praziquantel: the enigmatic antiparasitic. Parasitol. Today 8, 342-344.
19. Deardorff, M. A., Bando, M., Nakato, R., Watrin, E., Itoh, T., Minamino, M., et al. (2012). HDAC8 mutations in Cornelia de Lange syndrome affect the cohesin acetylation cycle. Nature 489, 313-317. doi: 10.1038/nature11316
20. de Moraes Maciel, R., da Costa, R. F., de Oliveira, F. M., Rumjanek, F. D., and Fantappié, M. R. (2008). Protein acetylation sites mediated by Schistosoma mansoni GCN5. Biochem. Biophys. Res. Commun. 370, 53-56. doi: 10.1016/j.bbrc.2008.03.022
21. Dissous, C., and Grevelding, C. G. (2010). Piggy-backing the concept of cancer drugs for schistosomiasis treatment: a tangible perspective? Trends Parasitol. 27, 59-66. doi: 10.1016/j.pt.2010.09.001
22. Doenhoff, M. J., Cioli, D., and Utzinger, J. (2008). Praziquantel: mechanisms of action, resistance and new derivatives for schistosomiasis. Curr. Opin. Infect. Dis. 21, 659-667. doi: 10.1097/QCO.0b013e328318978f
23. Dowden, J., Hong, W., Parry, R. V., Pike, R. A., and Ward, S. G. (2010). Toward the development of potent and selective bisubstrate inhibitors of protein arginine methyltransferases. Bioorg. Med. Chem. Lett. 20, 2103-2105. doi: 10.1016/j.bmcl.2010.02.069
24. Du, J., Zhou, Y., Su, X., Yu, J. J., Khan, S., Jiang, H., et al. (2011). Sirt5 is a NAD-dependent protein lysine demalonylase and desuccinylase. Science 334, 806-809. doi: 10.1126/science.1207861
25. Dubois, F., Caby, S., Oger, F., Cosseau, C., Capron, M., Grunau, C., et al. (2009). Histone deacetylase inhibitors induce apoptosis, histone hyperacetylation and up-regulation of gene expression in Schistosoma mansoni. Mol. Biochem. Parasitol. 168, 7-15. doi: 10.1016/j.molbiopara.2009.06.001
26. Eder, J., Sedrani, R., and Wiesmann, C. (2014). The discovery of first-in-class drugs: origins and evolution. Nat. Rev. Drug Discov. 13, 577-587. doi: 10.1038/nrd4336
27. Elring, A. M., Harb, J. G., Neviani, P., Garton, C., Oaks, J. J., Spizzo, R., et al. (2010). miR-328 functions as an RNA decoy to modulate hnRNP E2 regulation of mRNA translation in leukemic blasts. Cell 140, 652-665. doi: 10.1016/j.cell.2010.01.007
28. Fagan, R. L., Crydermand, D. E., Kopelovich, L., Wallraty, L. L., and Brenner, C. (2013). Laccaic acid A is a direct, DNA-competitive inhibitor of DNA methyltransferase 1. J. Biol. Chem. 288, 23858-23867. doi: 10.1074/jbc.M113.480517
29. Fallon, P. G., and Doenhoff, M. J. (1994). Drug-resistant schistosomiasis: resistance to praziquantel and oxamniquine induced in Schistosoma mansoni in mice is drug specific. Am. J. Trop. Med. Hyg. 51, 83-88.
30. Fantappié, M. R., Bastos de Oliveira, F. M., de Moraes Maciel, R., Rumjanek, F. D., Wu, W., and LoVerde, P. T. (2008). Cloning of SmNCoA-62, a novel nuclear receptor co-activator from Schistosoma mansoni: assembly of a complex with a SmRXR1/SmNR1 heterodimer, SmGCN5 and SmCBP1. Int. J. Parasitol. 38, 1133-1147. doi: 10.1016/j.ijpara.2008.02.003
31. Fantappié, M. R., Rodrigues, E., Gimba, P., and Rumjanek, F. D. (2001). Lack of DNA methylation in Schistosoma mansoni. Exp. Parasitol. 98, 162-166. doi: 10.1006/expr.2001.4630
32. Feldman, J. L., Dittenhafer-Reed, K. E., and Denu, J. M. (2012). Sirtuin catalysis and regulation. J. Biol. Chem. 287, 42419-42427. doi: 10.1074/jbc.R112.378877
33. Fenwick, A., Webster, J. P., Bosque-Oliva, E., Blair, L., Fleming, F. M., Zhang, Y., et al. (2009). The Schistosomiasis Control Initiative (SCI): rationale, development and implementation from 2002-2008. Parasitology 136, 1719-1730. doi: 10.1017/S0031182009990400
34. Filippakopoulos, P., and Knapp, S. (2014). Targeting bromodomains: epigenetic readers of lysine acetylation. Nat. Rev. Drug. Discov. 13, 337-356. doi: 10.1038/nrd4286
35. Filippakopoulos, P., Qi, J., Picaud, S., Shen, Y., Smith, W. B., Fedorov, O., et al. (2011). Selective inhibition of BET bromodomains. Nature 468, 1067-1073. doi: 10.1038/nature09504
36. Fromm, B., Worren, M. M., Hahn, C., Hovig, E., and Bachmann, L. (2013). Substantial loss of conserved and gain of novel microRNA families in flatworms. Mol. Biol. Evol. 30, 2619-2628. doi: 10.1093/molbev/mst155
37. Furdas, S. D., Shekfeh, S., Bissinger, E.-M., Wagner, J. M., Schlimme, S., Valkov, V., et al. (2011). Synthesis and biological testing of novel pyridoisothiazolones as histone acetyltransferase inhibitors. Bioorg. Med. Chem. 19, 3678-3689. doi: 10.1016/j.bmc.2011.01.063
38. Geyer, K. K., Chalmers, I. W., MacKintosh, N., Hirst, J. E., Geoghegan, R., Badets, M., et al. (2013). Cytosine methylation is a conserved epigenetic feature found throughout the phylum Platyhelminthes. BMC Genomics 14:462. doi: 10.1186/1471-2164-14-462
39. Geyer, K. K., Rodriguez Lopez, C. M., Chalmers, I. W., Munshi, S. E., Truscott, M., Heald, J., et al. (2011). Cytosine methylation regulates oviposition in the pathogenic blood fluke Schistosoma mansoni. Nat. Commun. 2, 424. doi: 10.1038/ncomms1433
40. Ghizzoni, M., Haisma, H. J., and Dekker, F. J. (2009). Reactivity of isothiazolones and isothiazolone-1-oxides in the inhibition of PCAF histone acetyltransferase. Eur. J. Med. Chem. 44, 4855-4861. doi: 10.1016/j.ejmech.2009.07.025
41. Goll, M. G., Kirpekar, F., Maggert, K. A., Yoder, J. A., Hsieh, C. L., Zhang, X., et al. (2006). Methylation of tRNA Asp by the DNA methyltransferase homolog Dnmt2. Science 311, 395-398. doi: 10.1126/science.1120976
42. Gregoretti, I. V., Lee, Y. M., and Goodson, H. V. (2004). Molecular evolution of the histone deacetylase family: functional implications of phylogenetic analysis. J. Mol. Biol. 338, 17-31. doi: 10.1016/j.jmb.2004.02.006
43. Greiss, S., and Gartner, A. (2009). Sirtuin/Sir2 phylogeny, evolutionary considerations and structural conservation. Mol. Cells 28, 407-415. doi: 10.1007/s10059-009-0169-x
44. Haigis, M. C., Mostoslavsky, R., Haigis, K. M., Fahie, K., Christodoulou, D. C., Murphy, A. J., et al. (2006). SIRT4 inhibits glutamate dehydrogenase and opposes the effects of calorie restriction in pancreatic beta cells. Cell 126, 941-954. doi: 10.1016/j.cell.2006.06.057
45. Hao, L., Cai, P., Jiang, N., Wang, H., and Chen, Q. (2010). Identification and characterization of microRNAs and endogenous siRNAs in Schistosoma japonicum. BMC Genomics 11:55. doi: 10.1186/1471-2164-11-55
46. Helin, K., and Dhanak, D. (2013). Chromatin proteins and modifications as drug targets. Nature 502, 480-488. doi: 10.1038/nature12751
47. Hermann, A., Schmitt, S., and Jeltsch, A. (2003). The human Dnmt2 has residual DNA-(cytosine-C5) methyltransferase activity. J. Biol. Chem. 278, 31717-31721. doi: 10.1074/jbc.M30544820
48. Hewings, D. S., Rooney, T. P., Jennings, L. E., Hay, D. A., Schofield, C. J., Brennan, P. E., et al. (2012). Progress in the development and application of small molecule inhibitors of bromodomain-acetyl-lysine interactions. J. Med. Chem. 55, 9393-9413. doi: 10.1021/jm300915b
49. Hojfeldt, J. W., Agger, K., and Helin, K. (2013). Histone lysine demethylases as targets for anticancer therapy. Nat. Rev. Drug. Discov. 12, 917-930. doi: 10.1038/nrd4154
50. Holt, C. A., and Roth, A. E. (2004). The Nash equilibrium: a perspective. Proc. Natl. Acad. Sci. U.S.A. 101, 3999-4002. doi: 10.1073/pnas.0308738101
51. Huang, J., Hao, P., Chen, H., Hu, W., Yan, Q., Liu, F., et al. (2009). Genome-wide identification of Schistosoma japonicum microRNAs using a deep-sequencing approach. PLoS ONE 4:e8206. doi: 10.1371/journal.pone.0008206
52. Hubbard, B. P., and Sinclair, D. A. (2014). Small molecule Sirt1 activators for the treatment of aging and age-related diseases. Trends Pharmacol. Sci. 35, 146-154. doi: 10.1016/j.tips.2013.12.004
53. Hubbert, C., Guardiola, A., Shao, R., Kawaguchi, Y., Ito, A., Nixon, A., et al. (2002). HDAC6 is a microtubule-associated deacetylase. Nature 417, 455-458. doi: 10.1038/417455a
54. Janssen, H. L., Reesink, H. W., Lawitz, E. J., Zeuzem, S., Rodriguez-Torres, M., Patel, K., et al. (2013). Treatment of HCV infection by targeting microRNA. N. Engl. J. Med. 368, 1685-1694. doi: 10.1056/NEJMoa1209026
55. Jiang, H., Khan, S., Wang, Y., Charron, G., He, B., Sebastian, C., et al. (2013). Sirt6 regulates TNF- secretion through hydrolysis of long-chain fatty acyl lysine. Nature 496, 110-113. doi: 10.1038/nature12038
56. Kohn, A. B., Anderson, P. A., Roberts-Misterly, J. M., and Greenberg, R. M. (2001). Schistosome calcium channel beta subunits. Unusual modulatory effects and potential role in the action of the antischistosomal drug praziquantel. J. Biol. Chem. 276, 36873-36876. doi: 10.1074/jbc.C100273200
57. Kovacs, J. J., Murphy, P. J., Gaillard, S., Zhao, X., Wu, J. T., Nicchitta, C. V., et al. (2005). HDAC6 regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor. Mol. Cell 18, 601-607. doi: 10.1016/j.molcel.2005.04.021
58. Kraus, V., and Reuter, G. (2011). DNA methylation in Drosophila - a critical evaluation. Prog. Mol. Biol. Transf. Sci. 101, 177-191. doi: 10.1016/B978-0-12-387685-0.00003-2
59. Kruidenier, L., Chung, C.-W., Cheng, Z., Liddle, J., Che, K., Joberty, G., et al. (2012). A selective jumonji H3K27 demethylase inhibitor modulates the proinflammatory macrophage response. Nature 488, 404-408. doi: 10.1038/nature11262
60. Lieberman, J., and Sarnow, P. (2013). Micromanaging hepatitis C virus. N. Engl. J. Med. 368, 1741-1743. doi: 10.1056/NEJMe1301348
61. Lancelot, J., Caby, S., Dubois-Abdesselem, F., Vanderstraete, M., Trolet, J., Oliveira, G., et al. (2013). Schistosoma mansoni sirtuins: characterization and potential as chemotherapeutic targets. PLoS Negl. Trop. Dis. 7:e2428. doi: 10.1371/journal.pntd.0002428
62. Li, Z., and Rana, T. M. (2014). Therapeutic targeting of microRNAs: current status and future challenges. Nat. Rev. Drug Discov. 13, 622-638. doi: 10.1038/nrd4359
63. Ling, H., Fabbri, M., and Calin, G. A. (2013). MicroRNAs and other non-coding RNAs as targets for anticancer drug development. Nat. Rev. Drug. Discov. 12, 847-865. doi: 10.1038/nrd4140
64. Maes, T., Tirapu, I., Mascaro, C., Ortega, A., Estiarte, A., and Valls, N. (2013). Preclinical characterization of a potent and selective inhibitor of the histone demethylase KDM1A for MLL leukemia. J. Clin. Oncol. 31(suppl.):e13543.
65. Marek, M., Kannan, S., Hauser, A. T., Moraes Mourão, M., Caby, S., Cura, V., et al. (2013). Structural basis for the inhibition of histone deacetylase 8 (HDAC8), a key epigenetic player in the blood fluke Schistosoma mansoni. PLoS Pathog. 9:e1003645. doi: 10.1371/journal.ppat.1003645
66. McCabe, M. T., Ott, H. M., Ganji, G., Korenchuk, S., Thompson, C., Van Aller, G. S., et al. (2012). EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. Nature 492, 108-112. doi: 10.1038/nature11606
67. Melman, S. D., Steinauer, M. L., Cunningham, C., Kubatko, L. S., Mwangi, I. N., Wynn, N. B., et al. (2009). Reduced susceptibility to praziquantel among naturally occurring Kenya isolates of Schistosoma mansoni. PLoS Negl. Trop. Dis. 3:e504. doi: 10.1371/journal.pntd.0000504
68. Messerli, S. M., Kasinathan, R. S., Morgan, W., Spranger, S., and Greenberg, R. M. (2009). Schistosoma mansoni P-glycoprotein levels increase in response to praziquantel exposure and correlate with reduced praziquantel susceptibility. Mol. Biochem. Parasitol. 167, 54-59. doi: 10.1016/j.molbiopara.2009.04.007
69. Metzger, E., Wissmann, M., Yin, N., Müller, J. M., Schneider, R., Peters, A. H., et al. (2005). LSD1 demethylates repressive histone marks to promote androgen-receptor dependent transcription. Nature 437, 436-439. doi: 10.1038/nature04020
70. Nakagawa, M., Oda, Y., Eguchi, T., Aishima, S.-I., Yao, T., Hosoi, F., et al. (2007). Expression profile of class I histone deacetylases in human cancer tissues. Oncol. Rep. 18, 769-774. doi: 10.3892/or.18.4.769
71. Nash, J. F. (1950). Equilibrium points in N-person games. Proc. Natl. Acad. Sci. U.S.A. 36, 48-49.
72. Nicodeme, E., Jeffrey, K. L., Schaefer, U., Beinke, S., Dewell, S., Chung, C.-W., et al. (2010). Suppression of inflammation by a synthetic histone mimic. Nature 468, 1119-1123. doi: 10.1038/nature09589
73. Norton, A. J., Gower, C. M., Lamberton, P. H., Webster, B. L., Lwambo, N. J., Blair, L., et al. (2010). Genetic consequences of mass human chemotherapy for Schistosoma mansoni: population structure pre- and post-praziquantel treatment in Tanzania. Am. J. Trop. Med. Hyg. 83, 951-957. doi: 10.4269/ajtmh.2010.10-0283
74. Ntziachristos, P., Tsirigos, A., Welstead, C. G., Trimarchi, T., Bakogianni, S., Xu, L., et al. (2014). Contrasting roles of histone 3 lysine 27 demethylases in acute lymphoblastic leukaemia. Nature. doi: 10.1074/jbc.C100273200. [Epub ahead of print].
75. Oger, F., Dubois, F., Caby, S., Noël, C., Cornette, J., Bertin, B., et al. (2008). The class I histone deacetylases of the platyhelminth parasite Schistosoma mansoni. Biochem. Biophys. Res. Commun. 377, 1079-1084. doi: 10.1016/j.bbrc.2008
76. Oliveira, K. C., Carvalho, M. L. P., Maracaja-Coutinho, V., Kitajima, J. P., and Verjovski-Almeida, S. (2011). Non-coding RNAs in schistosomes: an unexplored world. An. Acad. Bras. Cienc. 83, 673-694. doi: 10.1590/S0001-37652011000200026
77. Perrin, C., Lepesant, J. M., Roger, E., Duval, D., Fneich, S., Thuillier, V., et al. (2013). Schistosoma mansoni mucin gene (SmPoMuc) expression: epigenetic control to shape adaptation to a new host. PLoS Pathog. 9:e1003571. doi: 10.1371/journal.ppat.1003571
78. Piaz, F. D., Vassallo, A., Rubio, O. C., Castellano, S., Sbardella, G., and De Tommasi, N. (2011). Chemical biology of histone acetyltransferase natural compounds modulators. Mol. Divers. 15, 401-416. doi: 10.1007/s11030-010-9299-5
79. Pierce, R. J., Dubois-Abdesselem, F., Lancelot, J., Andrade, L., and Oliveira, G. (2012). Targeting schistosome histone modifying enzymes for drug development. Curr. Pharm. Des. 18, 3567-3578. doi: 10.2174/138161212801327248
80. Raddatz, G., Guzzardo, P. M., Olova, N., Fantappié, M. R., Rampp, M., Schaeffer, M., et al. (2013). Dnmt2-dependent methylomes lack defined DNA methylation patterns. Proc. Natl. Acad. Sci. U.S.A. 110, 8627-8631. doi: 10.1073/pnas.1306723110
81. Sayed, A. A., Simeonov, A., Thomas, C. J., Inglese, J., Austin, C. P., and Williams, D. L. (2008). Identification of oxadiazoles as new drug leads for the control of schistosomiasis. Nat. Med. 14, 407-412. doi: 10.1038/nm1737
82. Schaefer, M., and Lyko, F. (2010). Solving the Dnmt2 enigma. Chromosoma 119, 35-40. doi: 10.1007/s00412-009-0240-6
83. Schenk, T., Chen, W. C., Göllner, S., Howell, L., Jin, L., Hebestreit, K., et al. (2012). Inhibition of the LSD1 (KDM1A) demethylase reactivates the all-trans-retinoic differentiation pathway in acute myeloid leukemia. Nature Med. 18, 605-611. doi: 10.1038/nm.2661
84. Simoes, M. C., Lee, J., Djikeng, A., Cerqueira, G. C., Zerlotini, A., Silva-Pereira, R. A., et al. (2011). Identification of Schistosoma mansoni microRNAs. BMC Genomics 12:47. doi: 10.1186/1471-2164-12-47
85. Spannhoff, A., Hauser, A. T., Heinke, R., Sippl, W., and Jung, M. (2009). The emerging therapeutic potential of histone methyltransferase and demethylase inhibitors. CheMedChem 4, 1568-1582. doi: 10.1002/cmdc.200900301
86. Stefanic, S., Dvorak, J., Horn, M., Braschi, S., Sojka, D., Ruelas, D. Q., et al. (2010). RNA interference in Schistosoma mansoni schistosomula: selectivity, sensitivity and operation for larger-scale screening. PLoS Negl. Trop. Dis. 4:e850. doi: 10.1371/journal.pntd.0000850
87. Stolfa, D. A., Marek, M., Lancelot, J., Hauser, A. T., Walter, A., Leproult, E., et al. (2014). Molecular basis for the antiparasitic activity of a mercaptoacetamide derivative that inhibits histone deacetylase 8 (HDAC8) from the human pathogen Schistosoma mansoni. J. Mol. Biol. doi: 10.1016/j.jmb.2014.03.007. [Epub ahead of print].
88. Strahl, B., and Allis, C. (2000). The language of covalent histone modifications. Nature 403, 41-45. doi: 10.1038/47412
89. Streseman, C., and Lyko, F. (2008). Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine. Int. J. Cancer 123, 8-13. doi: 10.1002/ijc.23607
90. Sun, J., Wang, S., Li, C., Ren, Y., and Wang, J. (2014). Novel expression profiles of microRNAs suggest that specific miRNAs regulate gene expression for the sexual maturation of female Schistosoma japonicum after pairing. Parasit. Vectors 7:177. doi: 10.1186/1756-3305-7-177
91. Swinney, D. C., and Anthony, J. (2011). How were new medicines discovered? Nat. Rev. Drug. Discov. 10, 507-519. doi: 10.1038/nrd3480
92. Tan, M., Peng, C., Anderson, K. A., Chhoy, P., Xie, Z., Dai, L., et al. (2014). Lysine glutarylation is a protein posttranslational modification regulated by Sirt5. Cell Metab. 19, 605-617. doi: 10.1016/j.cmet.2014.03.014
93. Wang, Z., Xue, X., Sun, J., Luo, R., Xu, X., Jiang, Y., et al. (2010). An « in-depth » description of the small non-coding RNA population of Schistosoma japonicum schistosomulum. PLoS Negl. Trop. Dis. 4:e596. doi: 10.1371/journal.pntd.0000596
94. Warnecke, P. M., Stirzaker, C., Song, J., Grunau, C., Melki, J. R., and Clark, S. J. (2002). Identification and resolution of artifacts in bisulfite sequencing. Methods 27, 101-107. doi: 10.1016/S1046-2023(02)00060-9
95. West, A. C., and Johnstone, R. W. (2014). New and emerging HDAC inhibitors for cancer treatment. J. Clin. Invest. 124, 30-39. doi: 10.1172/JCI69738
96. Xue, X., Sun, J., Zhang, Q., Wang, Z., Huang, Y., and Pan, W. (2008). Identification and characterization of novel microRNAs from Schistosoma japonicum. PLoS ONE 3:e4034. doi: 10.1371/journal.pone.0004034
97. Yoo, C. B., and Jones, P. A. (2006). Epigenetic therapy of cancer. Past, present, and future. Nat. Rev. Drug Discov. 5, 37-50. doi: 10.1038/nrd1930
98. Young, N. D., Jex, A. R., Li, B., Liu, S., Yang, L., Xiong, Z., et al. (2012). Whole-genome sequence of Schistosoma haematobium. Nat. Genet. 44, 221-225. doi: 10.1038/ng.1065
99. Yuan, H., and Mamorstein, R. (2012). Structural basis for sirtuin activity and inhibition. J. Biol. Chem. 287, 42428-42435. doi: 10.1074/jbc.R112.372300
100. Zhou, Y., Zheng, H., Chen, Y., Zhang, L., Wang, K., Guo, J., et al. (2009). The Schistosoma japonicum genome reveals features of host-parasite interplay. Nature 460, 345-351. doi: 10.1038/nature08140